

International Conference
on
**THROMBOSIS
AND HEMOSTASIS ISSUES
IN CANCER**

Bergamo, Italy, November 2-4, 2001
Centro Congressi Giovanni XXIII



Platinum sponsor
Pharmacia Corporation

Gold sponsor
Novo Nordisk AS

Silver sponsors
Gruppo Lepetit SpA – Aventis Pharma Group
Crinos Industria Farmacobiologica SpA
Sanofi-Synthelabo SpA

Other sponsors
Pharmacia & Upjohn SpA
Instrumentation Laboratory SpA
Mediolanum Farmaceutici SpA
Cabru Sas
Aventis Behring SpA
Janssen-Cilag SpA
Schwarz Pharma SpA

International Conference
on
**THROMBOSIS
AND HEMOSTASIS ISSUES
IN CANCER**

Bergamo, Italy, November 2-4, 2001
Centro Congressi Giovanni XXIII

Program

CONFERENCE CHAIRMEN

Anna **FALANGA**

Department of Hematology-Oncology

Azienda Ospedaliera

Ospedali Riuniti di Bergamo

Largo Barozzi, 1

24128 Bergamo, ITALY

Benjamin **BRENNER**

Rambam Medical Center & Bruce

Rappaport Faculty of Medicine

Institute of Hematology

P.O. Box 9602,

Haifa 31096, ISRAEL

Frederick R. **RICKLES**

The George Washington University

Medical Center

Ross Hall 712E

2300 Eye St NW

Washington, DC 20037, USA

ORGANIZING COMMITTEE

Tiziano BARBUI

Benjamin BRENNER

Anna FALANGA

Guido FINAZZI

Roberto LABIANCA

Marina MARCHETTI

Galit SARIG

Frederick R. RICKLES

Alfonso VIGNOLI

ORGANIZING SECRETARIAT

Centro Congressi Giovanni XXIII,

Viale Papa Giovanni XXIII, 106

24121 Bergamo, Italy

Tel. +39.035.236435

Fax +39.035.236474

E-mail: ccongres@congresscenter.bg.it

infocon@congresscenter.bg.it





The meeting will be held under the auspices of:

*International Society
of Thrombosis and Haemostasis*

*Società Italiana per lo Studio
dell'Emostasi e della Trombosi*

Società Italiana di Ematologia

Associazione Italiana di Oncologia Medica

*Azienda Ospedaliera
Ospedali Riuniti di Bergamo*

*Ordine dei Medici Chirurghi e Odontoiatri
della Provincia di Bergamo*

*A.I.D.M.-M.W.I.A.
(Medical Women International Association)*

PROGRAM OVERVIEW

FRIDAY, 2

SATURDAY, 3

SUNDAY, 4

8.00
8.30
8.45
9.00
9.15
9.30
9.45
10.00
10.15
10.30
10.45
11.00
11.15
11.30
11.45
12.00
12.15
12.30
12.45
13.00
13.15
13.30
13.45
14.00
14.15
14.30
14.45
15.00
15.15
15.30
15.45
16.00
16.15
16.30
16.45
17.00
17.15
17.30
17.45
18.00
18.15
18.30
18.45
19.00
19.15
19.30
19.45
20.00
20.15
20.30

		Registration	Registration
		Plenary Session “Tumor cells and Hemostasis”	Plenary Session “Platelets, Fibrinolysis and Cancer”
		Coffee	Coffee
		Plenary Session “Angiogenesis”	Plenary Session “Prevention and Treatment of VTE in Cancer”
Registration		Lunch Session	Lunch
Satellite Symposia		Poster view	Poster Discussion
		Plenary Session “Epidemiological Aspects of Thrombosis in Cancer”	
Coffee		Tea / Coffee	Guide tour to the ancient Bergamo town
Satellite Symposia		Plenary Session “Systemic Syndromes”	
Opening remarks			
Roud Table			
Get-together Party			
	Gala Dinner		

SATELLITE SYMPOSIUM - SALA OGGIONI (ground floor)

Friday - November, 2nd 2001 13.30 - 18.00

13.30 - 15.30 NOVO NORDISK

Novoseven - a novel haemostatic agent to treat haemorrhage in cancer patients?

Chairmen's Introduction: *B. Brenner / M. Levi*

- NovoSeven a novel haemostatic agent. Mechanism of action. *D.M. Monroe*
- NovoSeven in acquired haemophilia. *M. von Depka*
- Reduction of perioperative blood loss and transfusion requirements by NovoSeven in patients undergoing Transabdominal prostatectomy. *M. Levi*
- Experience with NovoSeven on bleeding complications due to warfarin toxicity and platelets disorders. *C. Kessler*
- NovoSeven for treatment of bleeding in patients with thrombocytopenia, on vit. K- antagonist therapy and in partial hepatectomy due to liver cancer or benign tumors. Presentation of protocols. *K. Lollike*

Chairman's close. *B. Brenner*

16.15 - 18.00 PHARMACIA CORPORATION

LMWH: an integral component of cancer care?

Chairmen: *A. Falanga / S. Haas*

- Introductory remarks. *A. Falanga*
- VTE and cancer: epidemiology and pathogenesis. *P. Prandoni*
- Clinical Update: ongoing studies of dalteparin in cancer
Study designs and objectives:
- Randomized Comparison of Low molecular weight heparin versus Oral warfarin
Therapy for long term anticoagulation in cancer patients with venous thromboembolism (CLOT). *M. Levine*
- Evaluation of dalteparin in preventing catheter-related complications in cancer patients with central venous catheters. *A. Kretzschmar*
- Fragmin Advanced Malignancy Outcome Study (FAMOUS). *A.K. Kakkar*
- The use of LMWH in cancer thromboprophylaxis: an evolving paradigm. *A.K. Kakkar*
- Concluding remarks. *S. Haas*

SATELLITE SYMPOSIUM - SALA ALABASTRO (second floor)

Friday - November, 2nd 2001

14.00 - 15.45 SANOFI-SYNTHELABO

Deep Vein Thrombosis Risk in Cancer Patients

Chairmen's Introduction: *R. Labianca (Italy) - P. Prandoni (Italy)*

- The risk of venous thromboembolic events in cancer patients. *A. Piccoli*
- Unsolved issues in the management of venous thromboembolism in cancer patients. *G. Agnelli*
- Incidence of catheter-related central venous thrombosis. *A. Lee*
- The Pentasaccharide: a new frontier in thromboembolic prophylaxis. *M. M. Samama*
- The Pentasaccharide: first clinical results in very high-risk patients. *F. Piovella*

17.00 - 18.00 LEPETIT

Study shows prolonging treatment with enoxaparin reduces risk of thromboembolic complications in abdominal and pelvic cancer surgery

Chairman's Introduction: *T. Barbui*

Venous thromboembolism in cancer patients: expanding horizons.

Enoxacan II Clinical Trial. *G. Agnelli*

Discussion

Saturday - November, 3rd 2001

12.30 - 13.30 CRINOS

Lunch Session

Defibrotide and VOD (DF-VOD study):

operational aspects of a European large scale RCT

SCIENTIFIC PROGRAM

Friday - November, 2nd 2001

18.30 Opening remarks:

B. Brenner (Israel), A. Falanga (Italy), F.R. Rickles (USA)

19.00 Round table:

"How fundamental research has influenced clinical practice in haematology"

Chairman: *T. Barbui*

Panel Discussion: *T.A. Lister, P.M. Mannucci, U. Seligsohn, J. Wemlyen*

20.00 Get-together party at the Congress Center

Saturday - November, 3rd 2001

Plenary sessions:

TUMOR CELLS AND HEMOSTASIS

Chairmen: *A. Falanga (Italy), S.G. Gordon (USA)*

- | | | |
|------|--|--------|
| 8.30 | • Tumor cell prothrombotic properties. <i>A. Falanga (Italy)</i> | PL -01 |
| 8.50 | • Molecular regulation of blood clotting in tumor biology. <i>W. Ruf (USA)</i> | PL -02 |
| 9.10 | • Biochemistry of Cancer Procoagulant. <i>W. Mielicki (Poland)</i> | PL -03 |
| 9.30 | • Fibrinogen and tumor metastasis. <i>J. Degen (USA)</i> | PL -04 |

Selected Abstracts

- | | | |
|-------|---|--------|
| 9.50 | • Promotion of factor Xa and thrombin generation by T lymphoblastoid cell lines.
<i>T. Barrowcliffe et al. (UK)</i> | OC -01 |
| 10.00 | • Shear stress activation of HUVEC modulates the adhesion of tumor cells to the vessel wall.
<i>F. Fauvel-Lafève et al. (France)</i> | OC -02 |

10.15 Coffee break

ANGIOGENESIS

Chairmen: *F.R. Rickles (USA), R. Giavazzi (Italy)*

- | | | |
|-------|--|--------|
| 10.45 | • Relationship of blood clotting and tumor angiogenesis. <i>F.R. Rickles (USA)</i> | PL -05 |
| 11.05 | • Targeted delivery of tissue factor to tumor neovasculature for cancer therapy. <i>D. Neri (Italy)</i> | PL -06 |
| 11.25 | • Thrombospondin-1: An inhibitor of Angiogenesis. <i>G. Tarabozzi (Italy)</i> | PL -07 |
| 11.40 | • Inhibition of angiogenesis with heparin? <i>S.M. Smorenburg (The Netherlands)</i> | PL -08 |
| 11.55 | • The human vascular mapping project. Selection and utilization of molecules for tumor endothelial targeting. <i>W. Arap (USA)</i> | PL -09 |

Selected Abstracts

- | | | |
|-------|---|--------|
| 12.15 | • Inhibition of TF activity reduces network formation in an <i>in vitro</i> model of angiogenesis.
<i>N.J. James et al. (UK)</i> | OC -03 |
|-------|---|--------|

SCIENTIFIC PROGRAM

Saturday - November, 3rd 2001

12 30 *Lunch time*
Lunch session (look at Satellite Symposia Program)

13 30 **Poster view**

Plenary sessions:

EPIDEMIOLOGICAL ASPECTS OF THROMBOSIS IN CANCER

Chairmen: *M. H. Prins (The Netherlands), P. Prandoni (Italy)*

- | | | |
|--------------|---|---------------|
| 14 30 | • Venous thromboembolism and occult malignancy: An historical perspective.
<i>M. Prins (The Netherlands)</i> | PL -10 |
| 14 50 | • Screening for cancer in patients with venous thromboembolism.
<i>H. T. Sorensen (Denmark)</i> | PL -11 |
| 15 10 | • Idiopathic venous thromboembolism as a first manifestation of cancer.
<i>A. Piccoli (Italy)</i> | PL -12 |
| 15 30 | • A number needed to screen and cost-effectiveness analysis of the SOMIT-data
<i>H. M. O'ten (The Netherlands)</i> | PL -13 |

Selected Abstracts

- | | | |
|--------------|---|---------------|
| 15 45 | • The risk of venous thrombosis in cancer patients with or without the factor V Leiden mutation.
<i>J. Blom et al. (The Netherlands)</i> | OC -04 |
| 15 55 | • Malignant disease following pre-eclampsia: preliminary data from the Jerusalem perinatal study.
<i>S. Harlap et al. (USA)</i> | OC -05 |
| 16 15 | <i>Tea break</i> | |

SYSTEMIC SYNDROMES (E.G. DIC, TTP, NBTE)

Chairmen: *B. Brenner (Israel), J. Vermeylen (Belgium)*

- | | | |
|--------------|---|---------------|
| 16 30 | • Arterial thrombotic syndromes in cancer patients. <i>B. Brenner (Israel)</i> | PL -14 |
| 16 50 | • Autoimmune bleeding disorders in cancer patients. <i>P. M. Mannucci (Italy)</i> | PL -15 |
| 17 10 | • Cancer and DIC. <i>M. Levi (The Netherlands)</i> | PL -16 |
| 17 30 | • The coagulopathy of acute promyelocytic leukaemia. <i>F. Rodeghiero (Italy)</i> | PL -17 |

Selected Abstracts

- | | | |
|--------------|---|---------------|
| 17 50 | • Chemotherapy-induced activation of hemostasis: effects of a LMW heparin (dalteparin sodium) on plasma markers of hemostatic activation. <i>I. C. Weitz et al. (USA)</i> | OC -06 |
| 18 00 | • Two years experience with the collagen-binding assay for quantification of von-Willebrand-factor-cleaving protease (vWF-CP). <i>F. Bergmann et al. (Germany)</i> | OC -07 |

20 30 *Gala Dinner at Villa Caroli Zanchi - Stezzano*

SCIENTIFIC PROGRAM

Sunday - November, 4th 2001

Plenary sessions:

PLATELETS, FIBRINOLYSIS AND CANCER

Chairmen: *M. B. Donati (Italy), U. Seligsohn (Israel)*

- | | | |
|--------------|---|---------------|
| 8 30 | • Cancer metastasis: A model of cell-protease and cell-cell interactions.
<i>M. B. Donati (Italy)</i> | PL -18 |
| 8 50 | • Tumor cell-platelet interaction in metastatic disease.
<i>B. Felding-Habermann (USA)</i> | PL -19 |
| 9 10 | • u-PA and cell migration: Urokinase receptor as a ligand for a chemotactic G-protein-coupled receptor. <i>F. B. Lasi (Italy)</i> | PL -20 |
| 9 30 | • Properties and function of heparanase in cancer metastasis and angiogenesis.
<i>I. Vlodavsky (Israel)</i> | PL -21 |
| 9 50 | • Platelets cross-talk with tumor cells.
<i>D. Varon (Israel)</i> | PL -22 |
| 10 15 | <i>Coffee break</i> | |

PREVENTION AND TREATMENT OF VTE IN CANCER

Chairmen: *M. N. Levine (Canada), G. Agnelli (Italy)*

- | | | |
|--------------|--|---------------|
| 10 45 | • An overview of thromboprophylaxis in malignancy.
<i>A. Kakkar (UK)</i> | PL -23 |
| 11 05 | • Management of thromboembolic disease in cancer patients.
<i>M. N. Levine (Canada)</i> | PL -24 |
| 11 25 | • Antithrombotic agents in cancer survival.
<i>H. R. Buller (The Netherlands)</i> | PL -25 |

Selected Abstracts

- | | | |
|--------------|--|---------------|
| 11 45 | • Cantharox, a randomised controlled study comparing low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. <i>G. Meyer et al. (France)</i> | OC -08 |
| 11 55 | • Lower safety and probably lower efficacy of oral anticoagulation (OA) in cancer patients with venous thromboembolism (VTE). <i>G. Palareti et al. (Italy)</i> | OC -09 |
| 12 05 | • LMWH may improve long-term survival in patients with gastrointestinal cancer. <i>O. Thorlacius-Ussing et al. (Denmark)</i> | OC -10 |

12 30 *Lunch*

13 30 *Poster Discussion Sessions*

15 00 • Meeting closed

15 30 • Guided tour of ancient Bergamo town

POSTER PRESENTATIONS

Tumor cells and Hemostasis

Session I - Sala Stucchi

- PO -01** Do inflammatory adhesion molecules and the acute phase response have a role in chemotherapy induced hypercoagulability? *Kirwan CC, Torella F, McCollum CN, Byrne GJ*
- PO -02** LMWH and UFH counteract endothelial cell tissue factor (TF) expression induced by breast cancer cell media.
Vignoli A, Marchetti M, Barbui T, Falanga A
- PO -03** Tissue factor expression and increased VEGF secretion proceed with transition to adherent growth in a small cell lung cancer cell line.
Salge U, Boller K, Daubner E, Heiden M, Seitz R
- PO -04** Apoptosis induced by all-trans retinoic acid (ATRA) is associated with a reduction of procoagulant activity (PCA) in human breast cancer cells.
Marchetti M, Balducci D, Suardi S, Barbui T, Falanga A
- PO -05** Effects of 9-cis retinoic acid (9-cis RA) on the procoagulant activity (PCA) of breast cancer cells.
Balducci D, Marchetti M, Suardi S, Barbui T, Falanga A
- PO -06** Procoagulant activity of four T-lymphoblastoid cell lines: Role of tissue factor, phospholipid and cancer procoagulant.
Pickering W, Gray E, Goodall AH, Barrowcliffe TW
- PO -07** Is hyperfibrinogenemia in patients with small cell carcinoma of the lung inflammatory response to tumor cells?
Wajima T, Von Hoff DD

POSTER PRESENTATIONS

Angiogenesis and Antineoplastic Properties of Antithrombotic Agents Session I - Sala Stucchi

- PO -08** Sensitivity to anti-angiogenic compounds of endothelial cells derived from human tumors and normal tissues.
Dossi R, Bani MR, Alessandri G, Tarabozzi G, Giavazzi R
- PO -09** The tumor microenvironment modulates endothelial cell gene expression: Identification of a differentially expressed transcript.
Ghilardi C, Dossi R, Alessandri G, Bani MR, Giavazzi R
- PO -10** Tissue factor-mediated induction of capillary formation in vitro.
Ettele C, James NJ, Bruckdorfer KR
- PO -11** Thrombospondin-1 modulates angiogenic factors interaction with the extracellular matrix: A potential mechanism of TSP-1 antiangiogenic activity.
Margosio B, Vergani V, Borsotti P, Giavazzi R, Tarabozzi G
- PO -12** The interaction between endothelial and myeloma cells and the effects of verotoxin.
Molostvov G, Morris A, Rose P, Basu S
- PO -13** Expression of VEGF, MMP2 & MMP9 in plasma and ascites of patients affected by ovarian carcinoma.
Paganoni P, Manenti L, Floriani I, Tarabozzi G, Landoni F, Belotti D, Giavazzi R
- PO -14** PAI-1 is a molecular target for hyperthermia-mediated inhibition of angiogenesis.
Roca C, Primo L, Valdembrì D, Gabriele P, Cameli P, Cividalli A, Bussolino F
- PO -15** Combination of chemotherapy and anticoagulant drugs for the treatment of malignant tumors.
Sukhanov VA, Malchikova LP, Gerasimova LD
- PO -16** Anti-angiogenic efficacy and mechanism of the low molecular weight heparin, tinzaparin and tissue factor pathway inhibitor: Anti-cancer benefits.
Mousa SA
- PO -17** Anti-metastatic effect of low molecular weight heparin tinzaparin and tissue factor pathway inhibitor.
Amirkhosravi A, Francis J, Mousa SA
- PO -18** Anticoagulant in thrombosis and cancer: the missing link.
Mousa SA

POSTER PRESENTATIONS

Epidemiological aspects of thrombosis in cancer **Session II - Salvatore Stucchi**

- PO -19** The risk of a venous thrombotic event in lung cancer patients.
Blom JW, O'santo S, Rosendaal FR
- PO -20** Bilateral deep-vein thrombosis and cancer: Prospective study of 92 patients.
Bura A, Bienvenu B, Cailleux N, Leger P, Boccalon H, Fiessinger JN, Levesque H, Emmerich J
- PO -21** High incidence of thrombosis using G-CSF in the treatment of chemotherapy-induced neutropenia.
Cortesi E, Mancuso A, Moscetti L, Saltarelli R, Palma M
- PO -22** Acquired and genetic thrombotic risk factor in a young woman with recurrent TVP: A case report.
Dimicco P, Niglio A, Diadem MR, DeVita F, D'Uva M
- PO -23** The differences between clinical and autopsy outcomes in the thrombosis and bleeding in malignancies.
Penka M, Penka I
- PO -24** Mechanisms for acquired activated protein C resistance in cancer patients.
Sarig G, Michaleli Y, Lanir N, Brenner B, Haim N
- PO -25** The prevalence of inherited thrombophilia in patients with cancer: Preliminary findings.
Battistelli S, Ranalli M, Battistini S, Amato T, Sabatini L, Marrelli D, Mancini S

POSTER PRESENTATIONS

Systemic Syndromes (e.g. DIC, TTP, NBTE)

Session III - Sala Labastro B

- PO -26** Activated protein C resistance in non metastatic gastric cancer patients.
Dimicco P, Niglio A, Chirico G, Di Giuseppe D, Russo F, Federico A, Romano M, Torella R
- PO -27** Activation of coagulation in cancer: A mathematical model.
Sbignev AA, Khanin MA
- PO -28** Von Willebrand factor (VWF) in autologous stem cell transplantation.
Latuada A, Rosti A, Sacchi E, Calzarossa C, Russo U, Rossi E
- PO -29** Predictive model for the development of veno occlusive disease (VOD) following stem cell transplantation (SCT).
Zuckerman T, Gavish I, Avivi I, Eran A, Ben-Yehuda I, Sabo E, Lanir N, Rowe JM, Brenner B
- PO -30** Changes of coagulable hemostatic mechanism during cytostatic treatment of patients with cancer breast.
Petroviae D, Jovanoviae D
- PO -31** Bleeding and thrombosis in acute promyelocytic leukemia – a single center experience in 29 patients.
Dally N, Hoffman, Sarig G, Lanir N, JM Rowe, Brenner B
- PO -32** Thrombotic thrombocytopenic purpura (TTP) in cancer patients receiving chemotherapy: Evidence of increased nitric oxide production.
Porta C, Bobbio-Pallavicini E, Piovela F, Natalizi A, Ferrari S, Libré L, Danova M
- PO -33** Effectiveness of low molecular weight heparin (LMWH) in cancer-related disseminated intravascular coagulation (DIC). A case report.
Vitale F, Priolo D, Sambataro D, Colina P, Ferrà F
- PO -34** Cancer-related mild disseminated intravascular coagulation (mild DIC): A possible role for nadroparin therapy.
Vitale F, Priolo D, Rotondo S, Mattina M, Ferrà F
- PO -35** Hypercoagulability due to phenotypic APC resistance in primitive cerebral lymphoma.
De Lucia D, De Francesco F, Mavrotta R, Maito G, Sorrentino M, Papa ML

POSTER PRESENTATIONS

Platelets, Fibrinolysis and Cancer Session II - Sala Stucchi

- PO -36** Morphological and functional analysis of platelet VEGF in cancer patients.
Salgado R, Benoy I, Bogers J, Weytjens R, Vem eulen P, Hoylaerts M , D irix L, Van M ark E
- PO -37** PAI-5G/5G allele distribution in neoplastic patients with colon cancer.
C igolini M , Zem inian S, Barana D , O liani C , Cardinale C , Pignatti PF
- PO -38** Lipase, basic fibroblast growth factor, heparanase and cancer: Linking an altered biochemical profile with thrombosis, angiogenesis and metastasis.
Porta C ,D iani G ,Danova M ,Barone M , Serafini S, Piovela F
- PO -39** The role of fibrinolysis in chemotherapy induced hypercoagulability.
K irwan CC ,Ahm ed IJ, Torella F, M cCollum CN, Byrne G J
- PO -40** Pregnancy and abortion in women with Essential Thrombocythemia.
Candoni A, M ichelutti T, Dam iani D , Sperotto A, M ichelutti A, Cerno M , Fan in R, Baccarani M
- PO -41** Administration of GP IIB/IIIA inhibitors reduces subacute stent thrombosis in patients affected by cancer and acute coronary syndromes.
Sangiorgi G , Piovela F, Garratt K , De Tom a D , Barone M , M edda M , Balanescu S, Castelvechio S, Inglese L

POSTER PRESENTATIONS

Prevention and treatment of VTE in cancer

Session IV - Sala Labastro B

- PO -42** The risk of recurrence after a first episode of venous thromboembolism in cancer patients
Cosmi B, Legnani C, Coccheri S, Palareti G
- PO -43** Adverse interactions between continuous infusion of 5-Fluorouracil (5-FU) based chemotherapy and warfarin inducing prothrombin time abnormalities
Masci G, Zucali PA, Sarina B, Magagnoli M, Castagna L, Fallini M, Camaghi C, Santoro A
- PO -44** Incidence of newly diagnosed cancer after three months or one year of oral anticoagulation for a first episode of idiopathic venous thromboembolism
Taliani M R, Agnelli G, Prandoni P, Becattini C, Moia M, Bazzan M, Tomasi C, Guazzaloca C, Bertoldi A, Ageno W, Ambrosio GB, Salvi R, Poggio R, Silingardi M, Porro F, Zonzin P, Imberti D, Casazza F, Pogliani E, Ria L, Piovella F, De Lucia D, for the Warfarin Optimal Duration Italian Trial Investigators
- PO -45** Pulmonary artery sarcoma (angiosarcoma) mimicking chronic major vessel thromboembolic pulmonary hypertensive disease (CTPH)
Piovella F, Fedullo P, Barone M, Porta C, Serafini S, Ferrari S, Natalizi A, Librè L, Danova M
- PO -46** Cardiac thrombus associated angiosarcoma
Rothschild C, M assumoto CM
- PO -47** Femoral venous thrombosis in two patients with diffuse large cell lymphoma
Rothschild C, Loterio HA
- PO -48** Central venous line related thrombosis in children with acute lymphoblastic leucemia: A prospective study
Saracco P, Farinasso L, Gajno TM, Valori A, Campagnoli M F, Alliaudi C, Ferrero N, Cordero di Montezemolo L, Ramenghi U
- PO -49** High dose methotrexate in children with acute lymphoblastic leukemia: hyperhomocysteinemia, thrombotic risk and toxicity
Saracco P, Angelini P, Farinasso L, Barisone E, Campagnoli M F, Alliaudi C, Altare F, Bonetti F, Madon E
- PO -50** Pulmonary thromboembolism as presentation of acute myeloid leukemia, successfully treated with enoxaparin
Vallisa D, Imberti D, Bertè R, Cividati G, Moroni C, Lazzaro A, Cavanna L
- PO -51** Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
Prandoni P, Lensing AWA, Piccioli A, Noventa F, Bagatella P, Bernardi E, Girolami B, Marchiorri A, Sabbion P, Simioni P, Prins MH, Girolami A
- PO -52** Feasibility and safety of low dose warfarin prophylaxis of VTE in different categories of advanced cancer patients
Fagnani D, Tagliabue P, Pozzi P, Ferrario A, Cimminiello C
- PO -53** Comparison of in-patient admission vs nurse led ambulatory management of DVT: incidence of cancer at 6 months
Rhodes S, Bond S, Pemberton N, Green ES, Rose P, Brown R

AUTHOR INDEX

A

Ageno W PO44
 Agnelli G PO44
 Ahmed IJ PO39
 Alessandri G PO08, PO09
 Alliaudi C PO48, PO49
 Altare F PO49
 Amato T PO25
 Ambrosio GB PO44
 Amirkhosravi A PO17
 Angelini P PO49
 Angerhaus D OC07
 Arap W PL09
 Avivi I PO29

B

Baccarani M PO40
 Bagatella P PO51
 Balanescu S PO41
 Balducci D PO04, PO05
 Bani MR PO08, PO09
 Barana D PO37
 Barbui T PO02, PO04, PO05
 Barisone E PO49
 Barone M PO38, PO41, PO45
 Barrowcliffe TW OC01, PO06
 Basu S PO12
 Battistelli S PO25
 Battistini S PO25
 Bazzan M PO44
 Becattini C PO44
 Belotti D PO13
 Benoy I PO36
 Ben-Yehuda I PO29
 Bergmann F OC07
 Bernardi E PO51
 Bertè R PO50
 Bertoldi A PO44
 Bienvenu B PO20
 Blasi F PL20

Blom JW OC04, PO19
 Bobbio-Pallavicini E PO32
 Boccalon H PO20
 Bogers J PO36
 Boller K PO03
 Bond S PO53
 Bonetti F PO49
 Borsotti P PO11
 Brenner B, PL14, PO24,
 PO29, PO31
 Brill A PL22
 Brown R PO53
 Bruckdorfer KR OC03, PO10
 Budde U OC07
 Bura A PO20
 Bussolino F PO14
 Byrne GJ PO01, PO39

C

Cailleux N PO20
 Calzarossa C PO28
 Campagnoli MF PO48, PO49
 Cancelas J OC01
 Candoni A PO40
 Cardinale C PO37
 Carmeliet P PO14
 Carnaghi C PO43
 Casazza F PO44
 Castagna L PO43
 Castelvechio S PO41
 Cavanna L PO50
 Cerno M PO40
 Chirico G PO26
 Cigolini M PO37
 Cimminiello C PO52
 Civardi G PO50
 Cividalli A PO14
 Coccheri S OC09, PO42
 Colina P PO33
 Cordero Di Montezemolo L PO48

Cortesi E PO21
 Cosmi B OC09, PO42
 Cottu P OC08

D

D'uva M PO22
 Dally N PO31
 Damiani D PO40
 Danova M PO32, PO38, PO45
 Daubner E PO03
 De Francesco F PO35
 De Lucia D PO35, PO44
 De Toma D PO41
 De Vita F PO22
 Degen JL PL04
 Deutsch L OC05
 Di Giuseppe D PO26
 Di Micco P PO22, PO26
 Diadema MR PO22
 Diani G PO38
 Dirix L PO36
 Doggen CJM OC04
 Donati MB PL18
 Dossi R PO08, PO09

E

Emmerich J PO20
 Eran A PO29
 Ettelaie C OC03, PO10
 Extra JM OC08

F

Fabregas P OC01
 Fagnani D PO52
 Falanga A PL01, PO02, PO05,
 PO04
 Fallini M PO43
 Fanin R PO40
 Farge D OC08
 Farinasso L PO48, PO49

AUTHOR INDEX

- Fauvel-Lafeve F OC02
 Federico A PO26
 Fedullo P PO45
 Felding-Habermann B PL19
 Felez J OC01
 Ferrari S PO32, PO45
 Ferrario A PO52
 Ferraù F PO33, PO34
 Ferrero N PO48
 Fiessinger JN PO20
 Floriani I PO13
 Francis J PO17
 Friedlander Y OC05
- G
 Gabriele P PO14
 Gajno TM PO48
 Garratt K PO41
 Gavish I PO29
 Gerasimova LD PO15
 Ghilardi C PO09
 Giavazzi R PO08, PO09, PO11, PO13
 Girolami A PO51
 Girolami B PO51
 Goldshmidt O PL21
 Gomes N OC02
 Goodall AH PO06
 Gray E OC01, PO06
 Green ES PO53
 Gruel Y OC08
 Guazzaloca C PO44
- H
 Haim N PO24
 Harlap S OC05
 Heiden M PO03
 Hoffman R PO31
 Hoylaerts M PO36
- I
 Imberti D PO44, PO50
 Inglese L PO41
 Israel VK OC06
 Iversen LH OC10
- J
 James NJ OC03, PO10
 Jovanoviæ D PO30
- K
 Kakkar AK PL23
 Khanin MA PO27
 Kirwan CC PO01, PO39
 Knaanie A OC05
- L
 Landoni F PO13
 Lanir N PO24, PO29, PO31
 Lattuada A PO28
 Lazzaro A PO50
 Le Maignan C OC08
 Leger P PO20
 Legnani C OC09, PO42
 Legrand C OC02
 Lensing AWA PO51
 Levesque H PO20
 Levi M PL16
 Levine MN PL24
 Librè L PO32, PO45
 Liebman HA OC06
 Lorcerie B OC08
 Loterio HA PO47
- M
 Madon E PO49
 Magagnoli M PO43
 Maisto G PO35
 Malchikova LP PO15
- Mancini S PO25
 Mancuso A PO21
 Manenti L PO13
 Mannucci PM PL15
 Marchetti M PO02, PO04, PO05
 Marchiori A PO51
 Margosio B PO11
 Marjanovic Z OC08
 Marotta R PO35
 Marrelli D PO25
 Masci G PO43
 Massalha S OC05
 Massumoto CM PO46
 Mattina M PO34
 Mccollum CN PO01, PO39
 Medda M PO41
 Meyer G OC08
 Michaeli Y PO24
 Michelutti A PO40
 Michelutti T PO40
 Mielicki WP PL03
 Moia M PO44
 Molostvov G PO12
 Moroni C PO50
 Morris A PO12
 Moscetti L PO21
 Mousa SA PO16, PO17, PO18
- N
 Natalizi A PO32, PO45
 Neri D PL06
 Niglio A PO22, PO26
 Noventa F PO51
- O
 Okholm M OC10
 Olini C PO37
 Osanto S PO19
 Otten HMMB PL10, PL13

AUTHOR INDEX

P

Paganoni P PO13
 Palareti G OC09, PO42
 Palma M PO21
 Paltiel O OC05
 Palumbo JS PL04
 Papa ML PO35
 Pasqualini R PL09
 Pedersen L OC10
 Pemberton N PO53
 Penka I PO23
 Penka M PO23
 Petroviæ D PO30
 Piccioli A PL12, PO51
 Pickering W OC01, PO06
 Pignatti PF PO37
 Piovela F PO32, PO38,
 PO41, PO44, PO45
 Poggio R PO44
 Pogliani E PO44
 Porro F PO44
 Porta C PO32, PO38, PO45
 Pozzi P PO52
 Prandoni P PL12, PO44, PO51
 Presant C OC06
 Primo L PO14
 Prins MH PL10, PL13, PO51
 Priolo D PO33, PO34

R

Rabaneda M OC01
 Ramenghi U PO48
 Ranalli M PO25
 Rhodes S PO53
 Ria L PO44
 Rickles FR PL05
 Roca C PO14
 Rochanda L OC06
 Rodeghiero F PL17
 Romano M PO26

Rose P PO12, PO53
 Rosendaal FR OC04, PO19
 Rossi E PO28
 Rosti A PO28
 Rothschild C PO46, PO47
 Rotondo S PO34
 Roviello F PO25
 Rowe JM PO29, PO31
 Ruf W PL02
 Russo F PO26
 Russo U PO28

S

Sabatini L PO25
 Sabbion P PO51
 Sabo E PO29
 Sacchi E PO28
 Salgado R PO36
 Salge U PO03
 Saltarelli R PO21
 Salvi R PO44
 Sambataro D PO33
 Sangiorgi G PO41
 Santoro A PO43
 Saracco P PO48, PO49
 Sarig G PO24, PO31
 Sarina B PO43
 Sbignev AA PO27
 Schneppenheim R OC07
 Schuler U OC07
 Seitz R PO03
 Serafini S PO38, PO45
 Siegert G OC07
 Silingardi M PO44
 Simioni P PO51
 Smorenburg SM PL08
 Solal-Celigny P OC08
 Sørensen HT PL11, OC10
 Sorrentino M PO35
 Sperotto A PO40

Suardi S PO04, PO05
 Sukhanov VA PO15

T

Tagliabue P PO52
 Taliani MR PO44
 Taraboletti G PL07, PO08,
 PO11, PO13
 Thorlacius-Ussing O OC10
 Tiram E OC05
 Tomasi C PO44
 Torella F PO01, PO39
 Torella R PO26

V

Valcke J OC08
 Valdembri D PO14
 Vallisa D PO50
 Valori A PO48
 Van Marck E PO36
 Varon D PL22
 Vassy J OC02
 Vergani V PO11
 Vermeulen P PO36
 Vignoli A PO02
 Vitale F PO33, PO34
 Vlodavsky I PL21
 Von Hoff DD PO07

W

Waisman JR OC06
 Wajima T PO07
 Weitz IC OC06
 Weytjens R PO36

Z

Zeminian S PO37
 Zonzin P PO44
 Zucali PA PO43
 Zuckerman T PO29

GENERAL INFORMATION

Meeting venue

The Conference takes place in Bergamo at the:
Congress Center Giovanni XXIII
Viale Papa Giovanni XXIII, 106
24121 BERGAMO
ITALY
Phone: +39 035 236435
Fax: +39 035 236474

Registration desk

The registration desk is located in the hall of the Congress Center (Phone: +39 035 358960). It will be staffed continuously every day of the conference and the staff will help you with any enquiries that you may have. Facilities available at the registration desk include:

On-site registration

Registration fees as indicated in the second announcement for late registration.

Message boards

Any late changes in the program of the conference or personal messages will be notified here;

Telephone and fax

Available on request at the registration desk;

Computing, printing and xeroxing

Available on request at the registration desk.

Delegate Badges

All delegates are kindly requested to wear the badge throughout the Conference. Only badge holders will be admitted to the Conference, Exhibition, Get-together Cocktail, Coffee/Tea breaks, Lunches and Gala Dinner.

Name badges are coloured as follows:

Delegates	Red
Faculty	Blue
Sponsors	Green

Certificates of Attendance

Available at the information desk by 12.00 on Sunday 4 November.

Continuing Medical Education

The International Conference on Thrombosis and Hemostasis Issues in Cancer is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.be.

The International Conference on Thrombosis and Hemostasis Issues in Cancer is designated for a maximum of 9 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the education activity.

EACCME credits are recognized as Physician's Recognition award by the American Medical Association.

Evaluation questionnaire can be found in the Conference bags, please complete it and return it to the information desk.

Official poster sessions

The posters will be displayed in the Sala Stucchi (first floor) from 8.00 on Saturday 3 November through to 12.00 on Sunday 4 November.

The posters will be discussed on Sunday 4 November from 13.30 to 15.00:

Sessions I and II in the Sala Stucchi (first floor),
Sessions III and IV in the Sala Alabastro B (second floor).

Exhibition

The commercial exhibition is located in the foyer at the ground floor. The exhibition opening times are the same of the Conference.

GENERAL INFORMATION

Slide Center

Slide center is located at the ground floor closed to the registration desk. All presenters should check in their slides or diskette/CD-ROM containing a PowerPoint presentation no later than 2 hours prior to start of their session.

Language

The official language of the Conference is English. Translation will not be provided.

Local Transportation

There will be a bus service both in the morning and late afternoon between the conference site and hotels located outside the center of Bergamo.

Additional information about this service (timetable and meeting points) will be available at the reception of your hotel and at the registration desk.

Please check also at the registration desk the timetable and meeting points for the transfers to Villa Caroli Zanchi for the gala dinner scheduled on Saturday 3 November.

Meals

Coffee/tea breaks and lunches are included in the Conference fee and will be served in the Hall Bar (ground floor) and Sala Bianca (first floor). There are several dining facilities within walking distance of the Congress Center Giovanni XXIII. Ask for the list at the registration desk.

Bank

The Banca Popolare di Milano is in the same building as the Congress Center.

Cloakroom

Coats and bags may be left in the designated area at the ground floor.

Travel Agency

The Ovet Travel Agency is in the same building as the Congress Center.

Currency


The currency in Italy is the Italian lira.

Villa Caroli Zanchi (gala dinner venue)

Considered with good reason one of the most valuable and interesting Lombard villas, the residence Caroli-Zanchi in Stezzano (5 km from Bergamo) is a storic, artistic and cultural heritage of extraordinary value.

Built between 1836 and 1840 on Architect Giacomo Bianconi's project, is a marvellous example of architectural harmony: the Neoclassic style of the external is combined with the eclecticism of the internal, predominated by refined halls and small halls "on theme". Certainly country seat, but with a nobleness of soul and an expressivity such to compete without dread with the most prestigious residences.


GENERAL INFORMATION



GROUND FLOOR

GROUND FLOOR


- 1: Hall and Exhibition
- 2: Registration Desk
- 3: Exhibition
- 4: Sala Oggioni
- 5: Slide Center
- 6: Telephones
- 7: Cloakroom and Toilets
- 8: Catering



FIRST FLOOR

FIRST FLOOR

- 1: Posters
- 2: Garden
- 3: Catering



SECOND FLOOR

SECOND FLOOR

- 1: Sala Alabastro
- 2: Sala Novelli
- 3: Sala Stampa
- 4: Sala Ovale
- 5: Offices

SOCIAL EVENTS

Friday – November, 2nd 2001

20.00 Get-together party at the Congress Center

Saturday - November, 3rd 2001

For accompanying persons registered

8.45 Meeting point at Congress Center

9.00 Departure to Milan Downtown

10.30 Visit at Picasso Exhibit
(Milan - Palazzo Reale)

13.00 Quick lunch break

14.45 Visit to “L’Ultima Cena” (The Last Supper) by Leonardo da Vinci
(Milan - Church of Santa Maria delle Grazie)

15.00 Free shopping tour

17.00 Meeting point and departure to Bergamo

20.30 Gala Dinner at Villa Caroli Zanchi - Stezzano

Sunday – November, 4th 2001

For accompanying persons registered

9.30 Meeting point at Congress Center

10.00 Visit to “Accademia Carrara”

12.30 Buffet lunch at the congress center

15.30 Guided tour of the ancient Bergamo town

All delegates wishing to participate in the tour are requested
to confirm at the registration desk within 12.00 on Saturday 3 November

BERGAMO : CITY OF ART

History

Bergamo was founded on a hill by a first very old settlement in the protohistoric age, age which gave it the configuration that still characterizes it: the oldest part of the town, enclosed within walls, lays up on the hill while the modern centre has developed on the plain.

Celts, Goths, Romans, Lombards succeeded on the hill, but little can now be seen of them: some of the most important monuments date back to the Middle Ages.

The four centuries under the Venetian domination are the most significant period, when Venice and Bergamo were very close, both from an historical and a cultural point of view.

Piazza Vecchia

Piazza Vecchia, the heart of the old town, is enriched by such remarkable historical monuments as the Palazzo del Comune or Palazzo della Ragione, the Commune Tower, the Venetian Major's House and the Angelo May Library, formerly the town hall.

All round the Cathedral Square, a very religious area, are the Cathedral, St Maria Maggiore, the Colleoni Chapel and the Baptistery.

Churches

Built by Giovanni Antonio Amadeo by order of the famous *condottiero* Bartolomeo Colleoni, the Colleoni Chapel is one of the most significant examples of the lombard Renaissance. The Basilica of Santa Maria Maggiore was built to the glory of God by the people of the town in '200. The upper town gathers churches and monasteries which represent the most remarkable traces of the past such as Sant'Agostino and San Francesco. The church of S. Michele al Pozzo Bianco with its important collection of frescos dated '200 and '500 is one of the most charming places of upper Bergamo, where also Lorenzo Lotto worked in 1525.

The Walls


Developing for more than five kilometres, the still well-preserved town walls that encircle Bergamo on the hill are one of the most important evidence of bulwarks of the fifth century. Venice started their building in 1516 thus making Bergamo a fortress on the boundary with the State of Milan. The grand ring provided with four gateways offers a charming and very frequented promenade with foreshortened views on the modern town, the plain and the mountain. After being amazed at the charming skyline of towers and bell towers, those who want to reach the upper town have to pass through the imposing town- walls. The Castle of S. Vigilio, once part of the ancient fortification, offers you one of the most suggestive views of the old town. Two different cable railways take people from downtown either to the Castle or to the upper town


The old town lays amongst the greenery, to the advantage of the landscape. This strip of lush vegetation connects the historical town with the hill region extending westward. The territory, included in the regional park "Parco dei Colli" of Bergamo, is full of villas, farmhouses, vegetable gardens, gardens, woods and is enriched with some important historical and architectonic elements, such as the former monastery of Astino.

Accademia Carrara

The Accademia Carrara is one of the most important picture galleries in Italy. Its exhibition halls show paintings by world famous artists, including also some works of the most important artists of Bergamo. Paintings by Raffaello, Mantegna, Pisanello, Bellini, Botticelli, Carpaccio, Tiepolo, portraits by G.B. Moroni, V. Ghislandi (Fra' Galgario), L. Lotto.

MAP OF BERGAMO





- 1 Centro Congressi
Giovanni XXIII
- 2 Hotel Excelsior
San Marco
- 3 Best Western
Cappello d'Oro
- 4 Starhotel
Cristallo Palace
- 5 Una Hotel
- 6 Hotel Arli
- 7 Hotel Piemontese
- 8 Albergo
San Lorenzo
- 9 Central Parking
- 10 Youth Hostel



Conference Secretariat:
Centro Congressi Giovanni XXIII,
Viale Papa Giovanni XXIII, 106
24121 Bergamo, Italy
Tel. +39.035.236435 - Fax +39.035.236474
E-mail: ccongres@congresscenter.bg.it
infocon@congresscenter.bg.it

Scientific Secretariat:
Anna Falanga
Hematology-Oncology Department
Ospedali Riuniti di Bergamo
Largo Barozzi, 1
24128 Bergamo - Italy
E-mail: annafalanga@yahoo.com